126 related articles for article (PubMed ID: 25205514)
21. Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases.
Elsayed AA; Satou A; Eladl AE; Kato S; Nakamura S; Asano N
Histopathology; 2017 Mar; 70(4):579-594. PubMed ID: 27735994
[TBL] [Abstract][Full Text] [Related]
22. HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients.
Tan GW; Jiang P; Nolte IM; Kushekhar K; Veenstra RN; Hepkema BG; Jarrett RF; van den Berg A; Diepstra A
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830986
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Epstein-Barr virus strains and variants in classical Hodgkin's lymphoma by laser microdissection.
García-Cosío M; Santón A; Martín P; Reguero ME; Cristóbal E; Bellas C
Histol Histopathol; 2008 Feb; 23(2):209-17. PubMed ID: 17999377
[TBL] [Abstract][Full Text] [Related]
24. Mutation analysis of tumor necrosis factor alpha-induced protein 3 gene in Hodgkin lymphoma.
Etzel BM; Gerth M; Chen Y; Wünsche E; Facklam T; Beck JF; Guntinas-Lichius O; Petersen I
Pathol Res Pract; 2017 Mar; 213(3):256-260. PubMed ID: 28189285
[TBL] [Abstract][Full Text] [Related]
25. CTLA4 haploinsufficiency as a predisposition to classical Hodgkin lymphoma.
Mahat U; Terzioglu MK; Buhtoiarov I
Pediatr Hematol Oncol; 2020 Mar; 37(2):176-183. PubMed ID: 31971458
[TBL] [Abstract][Full Text] [Related]
26. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
27. Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases.
Lake A; Shield LA; Cordano P; Chui DT; Osborne J; Crae S; Wilson KS; Tosi S; Knight SJ; Gesk S; Siebert R; Hay RT; Jarrett RF
Int J Cancer; 2009 Sep; 125(6):1334-42. PubMed ID: 19507254
[TBL] [Abstract][Full Text] [Related]
28. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.
Ghesquières H; Maurer MJ; Casasnovas O; Ansell SM; Larrabee BR; Lech-Maranda E; Novak AJ; Borrel AL; Slager SL; Brice P; Allmer C; Brion A; Ziesmer SC; Morschhauser F; Habermann TM; Gaillard I; Link BK; Stamatoullas A; Fermé C; Dogan A; Macon WR; Audouin J; Cerhan JR; Salles G
Cytokine; 2013 Nov; 64(2):523-31. PubMed ID: 24008079
[TBL] [Abstract][Full Text] [Related]
29. Pathway-focused gene expression profiles and immunohistochemistry detection identify contrasting association of caspase 3 (CASP3) expression with prognosis in pediatric classical Hodgkin lymphoma.
Vera-Lozada G; Segges P; Stefanoff CG; Barros MHM; Niedobitek G; Hassan R
Hematol Oncol; 2018 Oct; 36(4):663-670. PubMed ID: 29901224
[TBL] [Abstract][Full Text] [Related]
30. Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.
Levin LI; Breen EC; Birmann BM; Batista JL; Magpantay LI; Li Y; Ambinder RF; Mueller NE; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1114-1123. PubMed ID: 28341757
[No Abstract] [Full Text] [Related]
31. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients.
Diepstra A; van Imhoff GW; Schaapveld M; Karim-Kos H; van den Berg A; Vellenga E; Poppema S
J Clin Oncol; 2009 Aug; 27(23):3815-21. PubMed ID: 19470931
[TBL] [Abstract][Full Text] [Related]
32. [Clinical features and prognosis of CD20-positive classical Hodgkin lymphoma].
Qin Y; Kang SY; He XH; Zhou SY; Liu P; Yang JL; Zhang CG; Yang S; Gui L; Shi YK
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2224-8. PubMed ID: 27480653
[TBL] [Abstract][Full Text] [Related]
33. Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's lymphoma in Brazil.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Assis MG; Eiras DP; Dobo C; Oliveira JS
Hematol Oncol; 2010 Sep; 28(3):137-41. PubMed ID: 20128016
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma.
Koh YW; Han JH; Yoon DH; Suh C; Huh J
Hematol Oncol; 2018 Feb; 36(1):182-188. PubMed ID: 28744882
[TBL] [Abstract][Full Text] [Related]
35. Pediatric Hodgkin lymphoma in a South Indian regional cancer center: its immunomorphology, tumor-associated macrophages, and association with Epstein-Barr virus.
Zameer MA; Premalata CS; Arunakumari B; Appaji L; Rao CR
Pediatr Hematol Oncol; 2015 May; 32(4):229-38. PubMed ID: 25252151
[TBL] [Abstract][Full Text] [Related]
36. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Montanari F; Diefenbach CS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):518-24. PubMed ID: 26351815
[TBL] [Abstract][Full Text] [Related]
37. Expression of retinoblastoma protein and P16 proteins in classic Hodgkin lymphoma: relationship with expression of p53 and presence of Epstein-Barr virus in the regulation of cell growth and death.
Kim LH; Peh SC; Poppema S
Hum Pathol; 2006 Jan; 37(1):92-100. PubMed ID: 16360421
[TBL] [Abstract][Full Text] [Related]
38. An Epstein-Barr virus-positive classical Hodgkin lymphoma with exclusive sinusoidal growth pattern: An unusual morphologic variant.
Su P; Jug R; Liu X; Wang E
Pathol Res Pract; 2017 Jun; 213(6):710-712. PubMed ID: 28552534
[TBL] [Abstract][Full Text] [Related]
39. Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.
Duffield AS; Ascierto ML; Anders RA; Taube JM; Meeker AK; Chen S; McMiller TL; Phillips NA; Xu H; Ogurtsova A; Berger AE; Pardoll DM; Topalian SL; Ambinder RF
Blood Adv; 2017 Jul; 1(17):1324-1334. PubMed ID: 29296775
[TBL] [Abstract][Full Text] [Related]
40. Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma.
Wein F; Weniger MA; Höing B; Arnolds J; Hüttmann A; Hansmann ML; Hartmann S; Küppers R
Cancer Immunol Res; 2017 Dec; 5(12):1122-1132. PubMed ID: 29070649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
